T-cell leukemia/lymphoma-1A predicts the clinical outcome for patients with stage II/III colorectal cancer
T-cell leukemia/lymphoma-1A predicts the clinical outcome for patients with stage II/III colorectal cancer
复制标题
DOI：
10.1016/j.biopha.2017.01.128
复制
发表时间：
2017-04-01
影响因子：
7.5
通讯作者：
Qin, Huanlong
中科院分区：
文献类型：
--
作者：
Li, Hao;Yan, Xuebing;Qin, Huanlong
T细胞白血病/淋巴瘤-1A（TCL1A）作为干细胞标志物在胚胎干细胞中大量表达，并已被确定为多种血液恶性肿瘤（如慢性淋巴细胞白血病和B细胞淋巴瘤）的癌基因。然而，关于其在实体瘤中的作用，可用的研究很少，并且针对结直肠癌（CRC）的研究更少。在本研究中，我们旨在调查 278 名 II/III 期 CRC 患者队列中 TCL1A 的表达和临床意义。结果发现，结直肠癌组织中TCL1A的表达高于癌旁正常组织，且与肿瘤分化程度、TNM分期和Ki-67阳性率显着相关。预后分析表明，TCL1A 表达是影响这些患者的 CRC 特异性和无病生存的独立因素。此外，我们发现TCL1A高表达的II/III期患者术后局部复发和转移率显着高于TCL1A低表达的患者。最后，通过亚组分析，我们发现TCL1A表达可以对接受标准辅助化疗的II/III期患者的结果进行分层。总而言之，我们的研究结果表明，TCL1A 不仅是 II/III 期 CRC 患者预后评估的有用生物标志物，而且还是改善其临床结果的有前景的治疗靶点。 (C) 2017 Elsevier Masson SAS。版权所有。
T-cell leukemia/lymphoma-1A (TCL1A) as a stem cell marker is abundantly expressed in embryonic stem cells and has been identified as an oncogene in various hematological malignancies such as chronic lymphocytic leukemia and B-cell lymphoma. However, with regard to its role in solid tumors, few studies are available and less are for colorectal cancer (CRC). In this study, we aim to investigate the expression and clinical significance of TCL1A in a cohort of 278 stage II/III CRC patients. As a result, we find TCL1A expression is higher in CRC tissues than that in adjacent normal tissues, and significantly correlated with tumor differentiation, TNM stage and Ki-67 positive rate. The prognostic analysis suggests that TCL1A expression is an independent factor affecting CRC-specific and disease-free survival of these patients. Furthermore, we find stage II/III patients with high TCL1A expression have a significantly higher rate of postoperative local recurrence and metastasis than those with low TCL1A expression. Finally, through subgroup analysis, we find TCL1A expression can stratify the outcome of stage II/III patients who received standard adjuvant chemotherapy. Taken together, our findings suggest TCL1A is not only a useful biomarker for prognostic evaluation in stage II/III CRC patients, but also a promising therapeutic target for improving their clinical outcome. (C) 2017 Elsevier Masson SAS. All rights reserved.